

REMARKS

The Amendment

Claims 1-22 were previously withdrawn as being directed to a non-elected invention. With this amendment, Applicants amend claims 1, 3, 5, 6, 14, and 15 to depend from claim 23, which the Examiner has indicated is allowable in its present form. Applicants cancel claims 2 and 7-12. Thus, claims 1, 3-6 and 13-22 now depend from an allowable claim. Applicants also amend claim 31 to include the term “and pharmaceutically acceptable salts thereof”.

The amendments are fully supported by the specification as filed. Accordingly, no new matter is added by the amendments. The Examiner is requested to enter the amendments.

Telephone Interview

Applicants thank Examiner Pihonak for the telephone interview on February 12, 2010, indicating allowability of the claims under active consideration. During this interview, Examiner Pihonak asked whether Applicants would like to rejoin the withdrawn method of treatment claims. With this response, Applicants amend the withdrawn method of treatment claims to depend from allowable claim 23. Applicants hereby request rejoinder of claims 1, 3-6 and 13-14, directed to a method for treating infertility in a mammal, and claims 15-22, directed to a method for treatment of a subject suffering from or susceptible to a disease or disorder associated with phosphodiesterase PDE4, adenosine transporters, or prostanoid receptors.

CONCLUSION

Applicants believe that the application is in good and proper condition for allowance.
Early notification of allowance is earnestly solicited.

Respectfully submitted,
HOWREY LLP

Dated: February 22, 2010

By: /David W. Clough /
David W. Clough, Ph.D.
Registration No.: 36,107
Customer No.: 22930
Telephone No.: (312) 595-1408

HOWREY LLP
ATTN: Docketing Department
2941 Fairview Park Drive, Suite 200
Falls Church, VA 22042-2924
Facsimile No.: (703) 336-6950